Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

117.52 +0.92 (+0.79%)
Streaming Delayed Price Updated: 9:43 AM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334,187
Open 116.73
Bid (Size) 117.50 (2)
Ask (Size) 117.55 (1)
Prev. Close 116.60
Today's Range 116.51 - 117.65
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
From Merck & Co., Inc.
Via Business Wire
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
Via Talk Markets

Performance

YTD
+3.78%
+3.78%
1 Month
-6.18%
-6.18%
3 Month
-6.80%
-6.80%
6 Month
-8.79%
-8.79%
1 Year
+7.89%
+7.89%

More News

Read More
MarketBeat Week in Review – 8/19 - 8/23
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Via Chartmill
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Via Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Via Talk Markets
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Via Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Via Benzinga
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.